{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:27:31Z","timestamp":1791210451576,"version":"4.1.0"},"reference-count":93,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG 22100 and IG 22204"],"award-info":[{"award-number":["IG 22100 and IG 22204"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Breast cancer is a heterogeneous disease with a high degree of diversity among and within tumors, and in relation to its different tumor microenvironment. Compared to other oncotypes, such as melanoma or lung cancer, breast cancer is considered a \u201ccold\u201d tumor, characterized by low T lymphocyte infiltration and low tumor mutational burden. However, more recent evidence argues against this idea and indicates that, at least for specific molecular breast cancer subtypes, the immune infiltrate may be clinically relevant and heterogeneous, with significant variations in its stromal cell\/protein composition across patients and tumor stages. High numbers of tumor-infiltrating T cells are most frequent in HER2-positive and basal-like molecular subtypes and are generally associated with a good prognosis and response to therapies. However, effector immune infiltrates show protective immunity in some cancers but not in others. This could depend on one or more immunosuppressive mechanisms acting alone or in concert. Some of them might include, in addition to immune cells, other tumor microenvironment determinants such as the extracellular matrix composition and stiffness as well as stromal cells, like fibroblasts and adipocytes, that may prevent cytotoxic T cells from infiltrating the tumor microenvironment or may inactivate their antitumor functions. This review will summarize the state of the different immune tumor microenvironment determinants affecting HER2+ breast tumor progression, their response to treatment, and how they are modified by different therapeutic approaches. Potential targets within the immune tumor microenvironment will also be discussed.<\/jats:p>","DOI":"10.3390\/cancers13246352","type":"journal-article","created":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T20:41:55Z","timestamp":1639946515000},"page":"6352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6475-0770","authenticated-orcid":false,"given":"Milena","family":"Perrone","sequence":"first","affiliation":[{"name":"Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Talarico","sequence":"additional","affiliation":[{"name":"Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-9969","authenticated-orcid":false,"given":"Claudia","family":"Chiodoni","sequence":"additional","affiliation":[{"name":"Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Sangaletti","sequence":"additional","affiliation":[{"name":"Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","article-title":"Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression","volume":"125","author":"Luond","year":"2021","journal-title":"Brit. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrc3726","article-title":"Hypoxia and the extracellular matrix: Drivers of tumour metastasis","volume":"14","author":"Gilkes","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","article-title":"The extracellular matrix modulates the hallmarks of cancer","volume":"15","author":"Pickup","year":"2014","journal-title":"EMBO Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7150\/jca.17648","article-title":"Role of tumor microenvironment in tumorigenesis","volume":"8","author":"Wang","year":"2017","journal-title":"J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rybinska, I., Mangano, N., Tagliabue, E., and Triulzi, T. (2021). Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073775"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.plipres.2017.11.002","article-title":"Adipocyte biology in breast cancer: From silent bystander to active facilitator","volume":"69","author":"Choi","year":"2018","journal-title":"Prog. Lipid Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the role of the tumor vasculature in antitumor immunity and immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/0008-5472.CAN-07-0912","article-title":"Tumor-associated macrophages press the angiogenic switch in breast cancer","volume":"67","author":"Lin","year":"2007","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9624760","DOI":"10.1155\/2017\/9624760","article-title":"Macrophages as Key Drivers of Cancer Progression and Metastasis","volume":"2017","author":"Nielsen","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15025","DOI":"10.1038\/npjbcancer.2015.25","article-title":"Tumor-associated macrophages: Unwitting accomplices in breast cancer malignancy","volume":"2","author":"Williams","year":"2016","journal-title":"NPJ Breast Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e002036","DOI":"10.1136\/jitc-2020-002036","article-title":"Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer","volume":"9","author":"Klopfenstein","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41588-019-0507-7","article-title":"The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies","volume":"51","author":"Angus","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: From TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jclinpath-2011-200355","article-title":"Tumour-infiltrating macrophages and clinical outcome in breast cancer","volume":"65","author":"Mahmoud","year":"2012","journal-title":"J. Clin. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000507055","article-title":"The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas","volume":"87","author":"Annaratone","year":"2020","journal-title":"Pathobiology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12282-016-0698-z","article-title":"Immune infiltrates in the breast cancer microenvironment: Detection, characterization and clinical implication","volume":"24","author":"Burugu","year":"2017","journal-title":"Breast Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamaoncol.2015.3239","article-title":"Association of Stromal Tumor-Infiltrating Lymphocytes with Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients with Early-Stage HER2-Positive Breast Cancer","volume":"2","author":"Perez","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","article-title":"CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes","volume":"130","author":"Liu","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10585-013-9602-9","article-title":"Predictive and prognostic factors in locally advanced breast cancer: Effect of intratumoral FOXP3+ Tregs","volume":"30","author":"Demir","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-08-2360","article-title":"Regulatory T Cells Recruited through CCL22\/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome","volume":"69","author":"Gobert","year":"2009","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13058-018-0942-x","article-title":"Prognostic impact of CD4-positive T cell subsets in early breast cancer: A study based on the FinHer trial patient population","volume":"20","author":"Schmidt","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"djw192","DOI":"10.1093\/jnci\/djw192","article-title":"Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer","volume":"109","author":"Bense","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e76379","DOI":"10.1371\/journal.pone.0076379","article-title":"Tumor Secretion of CCL22 Activates Intratumoral Treg Infiltration and Is Independent Prognostic Predictor of Breast Cancer","volume":"8","author":"Li","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1158\/0008-5472.CAN-18-1367","article-title":"Diverse Functions of Macrophages in Different Tumor Microenvironments","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-Associated Macrophages: From Mechanisms to Therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"ref_40","first-page":"4625","article-title":"Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma","volume":"56","author":"Leek","year":"1996","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"643771","DOI":"10.3389\/fimmu.2021.643771","article-title":"Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer","volume":"12","author":"Mehta","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3892\/ijo.2013.1938","article-title":"The role of tumor-associated macrophages in breast cancer progression","volume":"43","author":"Obeid","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.canlet.2013.01.024","article-title":"Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer","volume":"332","author":"Tang","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_44","first-page":"5407","article-title":"High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer","volume":"61","author":"Foekens","year":"2001","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6","article-title":"Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer","volume":"190","author":"Leek","year":"2000","journal-title":"J. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10961","DOI":"10.1038\/s41598-019-47375-2","article-title":"Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer","volume":"9","author":"Honkanen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of Tumor-Associated Neutrophil Phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_48","first-page":"2689","article-title":"Tumor-Associated Neutrophils in Breast Cancer Subtypes","volume":"18","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1245\/s10434-011-1814-0","article-title":"Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients","volume":"19","author":"Azab","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.7314\/APJCP.2014.15.23.10363","article-title":"Diagnostic and Prognostic Importance of the Neutrophil Lymphocyte Ratio in Breast Cancer","volume":"15","author":"Ozyalvacli","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12885-016-2352-8","article-title":"Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: A retrospective study","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3892\/mco.2016.1101","article-title":"An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer","volume":"6","author":"Iwase","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","article-title":"Myeloid-derived suppressor cells in breast cancer","volume":"140","author":"Markowitz","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1074\/jbc.M112.441402","article-title":"Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells","volume":"288","author":"Hix","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e56761","DOI":"10.1371\/journal.pone.0056761","article-title":"Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress","volume":"8","author":"Triulzi","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.celrep.2016.08.075","article-title":"Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity","volume":"17","author":"Sangaletti","year":"2016","journal-title":"Cell Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Salem","year":"2009","journal-title":"Cancer Immunol. Immun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.1016\/j.ebiom.2020.103055","article-title":"Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces","volume":"61","author":"Sangaletti","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1038\/s41467-018-04334-1","article-title":"Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity","volume":"9","author":"Nguyen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/0008-5472.CAN-20-2123","article-title":"Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers","volume":"81","author":"Hu","year":"2021","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15081","DOI":"10.1038\/ncomms15081","article-title":"Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer","volume":"8","author":"Chung","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41592-021-01065-y","article-title":"Method of the Year: Spatially resolved transcriptomics","volume":"18","author":"Marx","year":"2021","journal-title":"Nat. Methods"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s43018-021-00190-z","article-title":"Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response","volume":"2","author":"McNamara","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1038\/s41467-020-19494-2","article-title":"Pathologic and molecular responses to neoadjuvant trastuzumab and\/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)","volume":"11","author":"Hurvitz","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/bcr3067","article-title":"Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers\u2014Role of estrogen receptor and HER2 reactivation","volume":"13","author":"Wang","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-012-2067-8","article-title":"Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers","volume":"135","author":"Nahta","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40425-019-0548-6","article-title":"Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer","volume":"7","author":"Griguolo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-021-00163-6","article-title":"Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer","volume":"5","author":"Griguolo","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1158\/1078-0432.CCR-15-2021","article-title":"Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer","volume":"22","author":"Varadan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41416-018-0318-0","article-title":"Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit","volume":"119","author":"Triulzi","year":"2018","journal-title":"Brit. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.2019.37.15_suppl.574","article-title":"On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome","volume":"37","author":"Luen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1158\/1078-0432.CCR-21-1600","article-title":"Immune phenotype, HER2 addiction and breast cancer response","volume":"27","author":"Pizzamiglio","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/era.10.226","article-title":"HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies","volume":"11","author":"Gajria","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/jcp.29216","article-title":"Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy","volume":"235","author":"Derakhshani","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4\/6 Inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1038\/s41467-019-11729-1","article-title":"Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4\/6 inhibitor-resistant HER2-positive breast cancer","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): A single-arm, multicentre, phase 1b-2 trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/annonc\/mdx647","article-title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade","volume":"29","author":"Nuciforo","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fimmu.2017.01412","article-title":"Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer","volume":"8","author":"Solinas","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2(+) breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"Muller","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"14622","DOI":"10.1002\/jcp.28187","article-title":"CD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives","volume":"234","author":"Soleimani","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/15680096113139990073","article-title":"IDO+ DCs and Signalling Pathways","volume":"13","author":"Wang","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy with or without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.4049\/jimmunol.1402891","article-title":"Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fc gamma Receptors on Macrophages","volume":"194","author":"Shi","year":"2015","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2018.09.007","article-title":"Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages","volume":"175","author":"Su","year":"2018","journal-title":"Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Brit. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1758835919853971","DOI":"10.1177\/1758835919853971","article-title":"Neoadjuvant zoledronic acid for HER2-positive breast cancer: The Zo-NAnTax trial","volume":"11","author":"Crocamo","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/2326-6066.CIR-18-0070","article-title":"Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into CheckpointResponsive Tumors by Reprogramming Tumor-Infiltrating MDSCs","volume":"6","author":"Christmas","year":"2018","journal-title":"Cancer Immunol. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/24\/6352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:50:54Z","timestamp":1760169054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/24\/6352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":93,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13246352"],"URL":"https:\/\/doi.org\/10.3390\/cancers13246352","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]}}}